Which of the following is considered a first-line therapy for community-acquired pneumonia in outpatients?

Prepare for the NBME Form 11 Test with targeted flashcards and multiple-choice questions. Each question includes hints and explanations to aid learning. Boost your readiness for exam day!

Multiple Choice

Which of the following is considered a first-line therapy for community-acquired pneumonia in outpatients?

Explanation:
Outpatient CAP treatment aims to cover the bacteria that commonly cause the illness, including both typical pathogens like Streptococcus pneumoniae and atypical pathogens such as Mycoplasma and Chlamydophila. Azithromycin, a macrolide, provides that broad coverage in a simple, well-tolerated dosing regimen, making it a practical first-line choice for otherwise healthy outpatients. It handles the usual bacteria without needing complex schedules, which is why it’s favored in many exam scenarios. While amoxicillin targets the typical bacteria, it doesn’t reliably cover atypicals, and doxycycline, though effective, is not emphasized as the sole first-line option in this context. Levofloxacin is a broader agent reserved for patients with comorbidities, intolerance to first-line therapy, or prior treatment failure, due to concerns about resistance and side effects.

Outpatient CAP treatment aims to cover the bacteria that commonly cause the illness, including both typical pathogens like Streptococcus pneumoniae and atypical pathogens such as Mycoplasma and Chlamydophila. Azithromycin, a macrolide, provides that broad coverage in a simple, well-tolerated dosing regimen, making it a practical first-line choice for otherwise healthy outpatients. It handles the usual bacteria without needing complex schedules, which is why it’s favored in many exam scenarios. While amoxicillin targets the typical bacteria, it doesn’t reliably cover atypicals, and doxycycline, though effective, is not emphasized as the sole first-line option in this context. Levofloxacin is a broader agent reserved for patients with comorbidities, intolerance to first-line therapy, or prior treatment failure, due to concerns about resistance and side effects.

Subscribe

Get the latest from Passetra

You can unsubscribe at any time. Read our privacy policy